
|Videos|August 13, 2011
Dr. O'Shaughnessy on Continued Access to Avastin
Author(s)Joyce A. O'Shaughnessy, MD
Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Continued Access to Avastin
Advertisement
Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that all she truly needs is access to Avastin (bevacizumab) as a treatment option for breast cancer. She believes that with its many other approvals, both in the US and in the Europe, it will continue to be accessible with a large amount of information available on its use. Having tools, such as Avastin, readily available that are non-cross resistant with chemotherapy is necessary for patients with very few options left.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































